-
Statement from NCI Director Dr. Norman E. Sharpless on the Death of Senator John McCain
Senator John McCain, a long-time supporter of cancer research, passed away on August 25.
-
NCI-led research team develops predictor for immunotherapy response in melanoma
In a new study, NCI-led researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a type of immunotherapy.
-
Rosenberg, NCI-supported researchers to receive 2018 Albany Prize
NCI’s Steven A. Rosenberg, M.D., Ph.D., and two NCI-supported researchers have been named recipients of the 2018 Albany Medical Center Prize in Medicine and Biomedical Research for their pioneering immunotherapy research.
-
Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancer
Results from a randomized clinical trial show patients with HPV-positive oropharyngeal cancer treated with radiation and cetuximab had inferior survival compared to the current standard treatment with radiation and cisplatin. The trial’s goal was to find a less toxic treatment approach without compromising survival.
-
NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American men
RESPOND is the largest coordinated study on biological and non-biological factors associated with aggressive prostate cancer in African-American men. The study is an effort to learn why these men disproportionally experience aggressive disease.